Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8952411 | Brachytherapy | 2018 | 6 Pages |
Abstract
Heart doses were low in both groups. Expected increase in cardiac risk at these doses is minimal. It is unlikely that there will be a clinically significant difference in cardiac toxicity in patients treated with WBI-DIBH or PB-IORT. Further research is needed to evaluate the actual clinical impact of the observed cardiac doses delivered with these modalities.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Clayton Alonso, Einsley Janowski, Bruce Libby, Shayna Showalter,